Form 4 for PTN PALATIN TECHNOLOGIES INC
Accepted 2022-06-28 00:00:00 ET · period of report 2022-06-24 · accession 0001654954-22-008909 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-28 | 2022-06-24 | PTN | SPANA CARL | Pres, CEO, Dir | A - Grant | $0.00 | +43.5K | 10.53M | +0.4% | $0 |
| DM | 2022-06-28 | 2022-06-24 | PTN | SPANA CARL | Pres, CEO, Dir | A - Grant | $0.00 | +790.6K | 215.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-24 | A | A | 43,528 | $0.00 | 10,526,458 | D | — | — | (F1) Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-24 | A | A | 575,000 | $0.00 | 575,000 | D | $0.55 · 2025-06-22 to 2031-06-22 | 575,000 Common Stock | (F2) Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted time-based options to its executive officers which vest at the rate of 25% per year, starting in June 2022, contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-06-24 | A | A | 215,625 | $0.00 | 215,625 | D | $0.55 · 2025-06-22 to 2031-06-22 | 215,625 Common Stock | (F3) Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted performance-based options to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |